September 2022: Switzerland Update

An update posted on the Swissmedic website on September 05, 2022,  provides further details regarding an online information event, to cover the new and changed requirements and clarify the specifications in Switzerland, for in vitro diagnostic devices (IVDs). The event is scheduled to be held on November 3, 2022. Participation is free of charge and the presentation will be given in German with simultaneous interpretation into French. During the event, the slides will be shown in German and French.

Following the event, the slide sets will be published on the Swissmedic website in English, French, German and Italian.

The registration form for participating in the event is now available on the Swissmedic website. The deadline for registration is October 14, 2022.

The schedule and the list of speakers have also been published on the website.

More information can be found here.

May 2022: Switzerland Update

An update posted on the Kofam portal on May 27, 2022, informs users of the most important new developments and changes relating to clinical trials with in-vitro diagnostic products (IVDs) which  are regulated by the Ordinance on Clinical Trials with Medical Devices (ClinO-MD) from May 26, 2022.

According to the update, in addition to the existing obligation to prospectively register clinical trials with IVDs, the results of trials with IVDs must now also be published in a trial registry. This also applies to clinical trials with IVDs already underway when the ClinO-MD entered into force on 26 May 2022. The updated ClinO-MD is also now available.

The update further informs users of the categorization of IVDs and classification of clinical trials regulated under ClinO-MD into clinical investigation and performance studies.

An online information event, to cover the new and changed requirements and clarify the specifications in Switzerland will be held on  3 November 2022. Participation is free of charge and individual presentations will be provided on the Swissmedic website in German, French, Italian, and English a few days before the event.  The presentations during the event will be given in German and will be interpreted simultaneously into French. The event will not be recorded. The presentations can not be viewed at a later date.

More information can be found here.

May 2022: Switzerland Update

An update posted on the SwissMedic portal on May 26, 2022, informs users of the change in legal requirements for clinical trials with in-vitro diagnostic products (IVDs) in Switzerland.

From 26 May 2022, at the same time as the application of the In Vitro Diagnostics Regulation (IVDR) in the EU, clinical trials with in vitro diagnostic medical devices will be regulated in the Ordinance on Clinical Trials with Medical Devices (CTO-MedD) and no longer in the Ordinance on Clinical Trials (ClinO).

These new transitional periods in the EU have also been taken into account accordingly in the Swiss Ordinance on In Vitro Diagnostic Medical Devices (IvDO). To avoid jeopardizing a sufficient supply of medical devices to Switzerland, the Federal Council has set lengthy transitional periods – over one year for most devices – for designating the CH-REP.

More information can be found here.

Switzerland Update

An update posted on the Kofam portal on March 10, 2022, informs users of the change in legal requirements for clinical trials with in-vitro diagnostic products (IVDs) in Switzerland.

Clinical trials using IVDs, a special sub-group of medical devices, were regulated in the Clinical Trials Ordinance, (ClinO).  In the process of adapting the Swiss legislation to the new EU Medical Device Regulation (MDR) and the new EU regulation on IVDs (EU-IVDR), clinical research with IVDs in Switzerland will now also be regulated in the Ordinance on clinical trials with medical devices (ClinO-MD).

The changes would be effective from 26 May 2022, the same time as EU-IVDR.  From this date, the Clinical Trials Ordinance (ClinO) will only contain provisions for clinical trials with medicinal products, transplant products and transplantation, and other clinical trials.

Until the amended ClinO-MD comes into force, further information for applicants will be updated on the Kofam website, in a timely manner.

More information can be found here.

September 2021: Switzerland Update

New Application (VO) Form and New Format for Authorisation Applications and Changes/Notifications/Reports Regarding Clinical Trials with Medicinal Products as of 13 September 2021

According to an update posted by Swissmedic (Swiss Agency for Therapeutic Products), authorisation applications and changes/notifications/reports regarding clinical trials with medicinal products must be submitted to structure (“eDoc” structure), a new application form (“VO form”), and to a new address for submissions from 13 September 2021. Any submissions according to the old submission procedure will be deemed to be formally deficient. However, purely paperless submissions will not yet be possible as of 13 September 2021 and will be implemented at a later date. Therefore, the submissions would still be made on paper and on CD even after 13 September 2021, confirming that the files on the CD are identical with the paper documents.

For more information on the documents and instructions needed for the new procedure, please refer Clinical Trials on Medicinal Products.

August 2021: CTIS Webinar Update

European Medicines Agency updated the Clinical Trials Information System (CTIS) webinar: How sponsor organisations can prepare for CTIS event page with details pertaining to the webinar that took place on July 29, 2021.

It includes the following details provided for easy understanding of the working and functionalities of EU CTIS;

  1. Event Summary
  2. Documents inclusive of the agenda, list of speakers, and presentations over different aspects of EU CTIS
  3. Video recording of the webinar

August 2021- CTIS Highlights

The fourth issue of CTIS Highlights was published on August 06, 2021. It briefly discusses the new timeline for CTIS, confirming the go-live date of CTIS and the initial submission date followed by a three-year transition period for submission of ongoing trials through CTIS.

Additionally, the newsletter spans over the training programme updates, CTIS Sponsor handbook details, CTIS July Webinar in a word, and the importance of CTIS in harmonising the clinical trial regulatory submission process in the EU and EEA. It also fore say about another webinar that will be conducted on October 26, 2021, that will concern the preparation of CTIS from the end-user perspective. Further information on this will be provided on the EMA event page and future CTIS newsletters.

For more information, click here.



August 2021: CTIS Training Update

Dissemination guidelines for training materials: CTIS training programme

European Medicines Agency published a new guideline document related to the Clinical Trial Information System (CTIS) training programme, on August 05, 2021.

This guide is intended to support instructors in using the training materials prepared for the CTIS Training Programme. It is suggested that trainers follow a blended learning approach combining asynchronous with synchronous activities for an optimal learning experience of end-users while making efficient use of their time.

Combining the two training methods, by sharing some materials with participants ahead of a real-time training session, will ensure that participants can assimilate some contents individually and reflect on questions they may have. The training session can then be used to check participants’ knowledge absorption, address their questions, and collect input on the training materials and methodology.

For more information, refer to the guideline here.

July 2021: Clinical Trial Data Reporting in EU Countries

In Europe, the enthusiasm for trials is not matched with a zeal for reporting the results to the public. Nearly 28% of completed European trials in the EU Clinical Trials Register (EUCTR) on 1 July—had not posted their results according to the latest data from the EU Trials Tracker, set up by U.K. researchers in 2018. Public research hospitals and universities are responsible for the vast majority of the lapses, which appear to violate European rules that require sponsors to post their results within 1 year of a trial’s conclusion.

Some researchers from public trial centers aren’t keen to disclose negative results and others believe publishing results in a journal fulfills the reporting requirement, even though journal articles can come years later and are often not made public. The Public Assistance Hospitals of Paris (AP-HP), the largest clinical trial center in Europe has reported results for just one of 35 trials completed more than 12 months ago, according to the EU tracker. More than 200 of the center’s trials are listed on EUCTR as ongoing, even though more than half of them began more than 10 years ago.

The current rules stem from 2001 European guidelines are considered as “soft legislation” and some nations seem to be taking advantage. According to current French regulations, there is no obligation to post results in the EU database, their priority has been to publish both positive and negative results in peer-reviewed journals. In the Netherlands, it is sufficient if sponsors post results in the Dutch trial registry, run by the Central Committee on Research Involving Human Subjects (CCMO). The CCMO website states that sponsors must also post results of medicines trials in the EU database, but Amsterdam University Medical Center (AUMC) does not follow that rule seeing any advantage in double registrations or in doubling researchers’ administrative burden.

Europe is getting more serious about enforcing the reporting requirements. Since the launch of the EU tracker in 2018, timely reporting of results has risen from 50% to 72% of completed trials. The European Medicines Agency (EMA) has stepped up reminders to trial leaders and has sent out about 30,000 reminders to overdue trial sponsors since 2018, another possible driver of improvement. Special notices go out for COVID-19 trials.

EMA’s new trial registry Clinical Trials Information System (CTIS) launch scheduled for Jan 2022 will eventually replace the EUCTR portal after a 3-year transition period and will end the tedious process of registering trials in each participating country. Sponsors will upload all trial data, from start to finish and the relevant national regulators will review the data before the information becomes public in one, linear, straight-through process. Once CTIS goes live, a 2014 European regulation will take effect, empowering national regulators in the European Economic Area to enforce the reporting of results. It will be for governments to decide how the national regulators should enforce reporting and what penalties they should impose for lapses.

Denmark, known for its vigilant regulation of drugs and trials already has a law that allows authorities to fine or imprison clinical trial leaders who do not meet deadlines for reporting results.

Additional details are found here.

June 2021: CTIS Update

The third issue of CTIS Highlights was published on June 23, 2021.

It discusses two user management approaches (organization-centric and trial-centric) and the process of assigning roles in CTIS.

The other topics covered are CTIS system functionalities, Initial clinical trial application process in CTIS, Training Programme update and Audit updates. Additionally, it announces the availability of a CTIS Sponsor Handbook. EMA, in a collaborative approach including sponsor representatives, will prepare a sponsor handbook to provide sponsors with an overview of materials available to help them prepare for and use CTIS. A first version is expected to be published in Q3 2021.